The Cancer Researcher
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
The Cancer Researcher
No Result
View All Result

The EACR’s Top 10 Cancer Research Publications: February 2022

October 17, 2025
EACR top 10 cancer research publications

The EACR’s Top 10 Cancer Research Publications is a regular summary of the most interesting and impactful recent papers in cancer research. It is curated by the Board of the European Association for Cancer Research (EACR).

The list below appears in no particular order, and the summary information has been provided by the authors.

Use the dropdown menu or ‘Previous’ and ‘Next’ buttons to navigate the list.

8. Multi-omic machine learning predictor of breast cancer therapy response

  • 1. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
  • 2. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
  • 3. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
  • 4. Dietary palmitic acid promotes a prometastatic memory via Schwann cells
  • 5. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
  • 6. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
  • 7. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
  • 8. Multi-omic machine learning predictor of breast cancer therapy response
  • 9. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
  • 10. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Previous
Next

Sammut, SJ., Crispin-Ortuzar, M., Chin, SF. et al. Nature 601, 623–629 (2022).

Summary of the findings

Despite great strides in understanding the biology of cancer, we still cannot reliably predict response to chemotherapy (plus HER2-targeted therapy for ERBB2 amplified tumours). In this study, we aimed to: (a) understand the biological processes associated with response to chemotherapy in breast cancer and (b) build a machine learning framework that combines pre-therapy molecular and digital pathology data to predict response.

We molecularly profiled breast tumour biopsies obtained at diagnosis from 168 women using exome and RNA sequencing and analysed their histological architecture using digital pathology. Women received 18 weeks of pre-operative chemotherapy and response was assessed at surgery using the Residual Cancer Burden score.

The baseline pre-therapy features were monotonically associated with response. DNA features associated with response related to genomic instability, including tumour mutation and neoantigen burden, homologous recombination deficiency and TP53 mutations. Response to therapy was also modulated by the tumour immune microenvironment. Specifically, high lymphocyte density, lack of T-cell dysfunction and exclusion, and absence of HLA class I loss of heterozygosity were associated with a better outcome.

Combining these molecular and digital pathology features into a multi-omic machine learning model predicted a pathological complete response in an external validation cohort with an area under curve of 0.87.

A tweetorial describing this study can be found at: https://twitter.com/stephensammut/status/1468251380586590216

Future impact of the findings

By integrating highly dimensional multi-omic data generated by profiling the tumour ecosystem, we have increased our understanding of the biology of breast cancer and developed a framework that will transform the way we treat it. In the future, this framework could be used to determine which patients can be treated with standard of care therapies (if they are predicted to respond) or treated using novel therapies in clinical trials (if predicted to be resistant to standard therapies). Perhaps more importantly, this approach has demonstrated a new way of thinking about forecasting therapy response which could be adapted for use in other cancer types.

Read more in Nature

8. Multi-omic machine learning predictor of breast cancer therapy response

  • 1. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
  • 2. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
  • 3. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
  • 4. Dietary palmitic acid promotes a prometastatic memory via Schwann cells
  • 5. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
  • 6. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
  • 7. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
  • 8. Multi-omic machine learning predictor of breast cancer therapy response
  • 9. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
  • 10. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Previous
Next
Tags: EACR Top Ten Cancer Research Publications

Related Posts

“The visit represented a complete shift in how I think about research.” – José Antonio Torres Alcaide’s Travel Fellowship

“The visit represented a complete shift in how I think about research.” – José Antonio Torres Alcaide’s Travel Fellowship

July 27, 2026

José Antonio Torres Alcaide is a PhD student at the Spanish National Cancer Research Center (CNIO) who received an EACR Travel Fellowship to visit and work...

“A community that actively supports growth, resilience, and global collaboration” – what EACR membership means to a researcher from a low-income country

“A community that actively supports growth, resilience, and global collaboration” – what EACR membership means to a researcher from a low-income country

July 13, 2026

We caught up with Mounia Benbelkacem, a PhD researcher at the Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, University of Science and Technology...

“Reinforced my desire to build and develop computational and bioinformatics capacity”- Aniefiok John Udoakang’s Travel Fellowship

“Reinforced my desire to build and develop computational and bioinformatics capacity”- Aniefiok John Udoakang’s Travel Fellowship

July 8, 2026

Aniefiok John Udoakang is a postdoctoral researcher at University of Medical Sciences, Ondo City, Ondo State, Nigeria who received an EACR Travel Fellowship to visit and...

The Cancer Researcher EACR logo

About Us

The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.

The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”

Advertisement Advertisement Advertisement
ADVERTISEMENT

RECENT POSTS

“The visit represented a complete shift in how I think about research.” – José Antonio Torres Alcaide’s Travel Fellowship
Career

“The visit represented a complete shift in how I think about research.” – José Antonio Torres Alcaide’s Travel Fellowship

July 27, 2026
“For me, the Ambassador role has had a very real impact in terms of networking” – Hamdullah Khadim Sheikh reflects on his EACR membership
Career

“For me, the Ambassador role has had a very real impact in terms of networking” – Hamdullah Khadim Sheikh reflects on his EACR membership

July 27, 2026
The Cancer Researcher

© 2025 EACR

Navigate site

  • About
  • Privacy
  • Main EACR website

Follow us

No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious

© 2025 EACR